Navigation Links
Should children be permitted to get genetic testing for BRCA 1/2 mutations?
Date:1/15/2008

PHILADELPHIA -- Its an ethical dilemma with serious implications. Should children be tested for gene mutations that predispose them to developing breast cancer and/or ovarian cancer later in life" New research suggests the next generation of parents may support testing minors even when any steps to reduce that risk will be postponed until adulthood a finding that challenges current policies.

In the study published today online in the American Journal of Medical Genetics (Vol. 148C, Feb. 15, 2008 in print), researchers surveyed 53 BRCA mutation carriers who had children under 25 years of age at the time they received their genetic test results. In addition, 22 adult offspring of these parents were interviewed. The majority of parent participants were mothers (89%) although the offspring included both sons (45%) and daughters (55%). Interview subjects were recruited through the University of Chicago Cancer Risk Clinic.

Combining the responses of parents and offspring, 40% supported genetic testing of minors with half in favor only in certain circumstances. A majority of sons and daughters potential consumers of genetic testing, supported testing minors.

The latter finding is interesting, said lead author Angela Bradbury, M.D., of Fox Chase Cancer Center. It signals that the next generation may be more comfortable with genetic testing. This could be because their generation grew up with genetics, learning about it in school or from the news, unlike their parents. To them, genetic testing may not be exceptional.

A majority of professional groups recommend against the genetic testing of minors in the absence of medical benefit. Carriers of a BRCA 1/2 mutations will not necessarily develop cancer but their risk is increased. Men with an alteration, face an increased risk of developing prostate, breast and pancreatic cancer. Women with an alteration are at an increased risk of developing breast and/or ovarian cancer. Risk reduction options
'/>"/>

Contact: Frank Hoke
Franklin.Hoke@fccc.edu
215-728-2700
Fox Chase Cancer Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Fisheries should be regarded as a part of the maritime environment
2. BMI criteria for obesity surgery should be lowered, UT Southwestern researcher suggests
3. Researchers find association between food insecurity and developmental risk in children
4. Scientists study the link between childrens nutrition and adult diseases
5. Device prevents potential errors in childrens medications
6. Childrens Hospital neurosurgeon receives grant
7. New screening strategy for detection of chagas disease in children
8. Study shows immigrant children are at increased risk of lead poisoning
9. Family ties that bind: Maternal grandparents are more involved in the lives of their grandchildren
10. PET/CT imaging proves golden for detecting cancer in children
11. Even minute levels of lead cause brain damage in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... the Advancement of Science (AAAS) has named Dr. J. ... University of Colorado School of Medicine, as winner of ... Award., Cohen was honored for his outstanding achievements in ... series of free lectures on science and medicine, informal ...
... ANN ARBOR, Mich.---Rising carbon dioxide levels associated with global ... that eat them, altering the course of plant evolution, ... The research focused on the effects of elevated carbon ... of many plants that produce toxic or bitter chemical ...
... short stature is not usually cause for concern, but it ... syndrome. Prevalent in girls, Turner syndrome is a genetic defect ... problems. It is not commonly detected until age 10 or ... This lag before diagnosis of the condition can delay ...
Cached Biology News:Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 2Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 3Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award 4Global warming may reroute evolution 2New test shows promise for accurate diagnosis of Turner syndrome 2
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... are quickly eliminated from the body. Scientists at the ... a kind of molecular balloon that swells and thus ... The TUM spin-off XL-protein GmbH has now started to ... People who suffer from hepatitis B are often treated ...
... WOBURN, Mass., Sept. 21 The Center for Business Intelligence ... the proceeds from their Alzheimer,s Drug Development Summit to the ... this week, September 21-25, 2009, in recognition of World Alzheimer,s ... Alzheimer,s associations, globally, to raise awareness and encourage citizens to ...
... NEW YORK, Sept. 21 Emissary Capital Group, ... (OTC Bulletin Board: SNBP) with a Buy rating and ... domestically as Dong Ying Pharmaceutical Co. Ltd., is a ... R&D, manufacture and distribution of biopharmaceutical products. The ...
Cached Biology Technology:Researchers prolong the plasma half-life of biopharmaceutical proteins 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 3Emissary Capital Group Initiates Coverage on Sinobiopharma 2
FEN-1 (B-4)...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: